Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Ursodeoxycholic acid UDCA

Importantly, knowledge of intestinal bile acid transport and metabolism, coupled with increased understanding of the mechanistic basis of the pro-tumorigenic activity of bile acids against CRC cells in vitro, has recently led to development and testing of bile acid-based treatment and prevention strategies for sporadic and inflammatory bowel-disease-associated CRC. Existing evidence that manipulation of the luminal secondary bile acid pool and/or therapy with ursodeoxycholic acid (UDCA) may have promise for prevention of CRC will be assessed. [Pg.84]

Figure 5.2 Therapeutic interventions for decreasing colorectal mucosal bile acid exposure as a CRC chemoprevention strategy. 1) Lifestyle modifications including reduction in dietary animal fat and increased fibre intake may, at least partly, be explained by reduction in luminal primary (cholic acid [CA] and chenodeoxycholic acid [CDCA]) and secondary (deoxycholic acid [DCA] and lithocholic acid [LCA]) bile acids. 2) Reduction of secondary bile acids, which are believed to have pro-carcinogenic activity could be obtained by decreased bacterial conversion from primary bile acids. 3) Alternatively, bile acids could be sequestered by chemical binding agents, e.g. aluminium hydroxide (Al(OH)3) or probiotic bacteria. 4) Exogenous ursodeoxycholic acid (UDCA) can reduce the luminal proportion of secondary bile acids and also has direct anti-neoplastic activity on colonocytes in vitro. Figure 5.2 Therapeutic interventions for decreasing colorectal mucosal bile acid exposure as a CRC chemoprevention strategy. 1) Lifestyle modifications including reduction in dietary animal fat and increased fibre intake may, at least partly, be explained by reduction in luminal primary (cholic acid [CA] and chenodeoxycholic acid [CDCA]) and secondary (deoxycholic acid [DCA] and lithocholic acid [LCA]) bile acids. 2) Reduction of secondary bile acids, which are believed to have pro-carcinogenic activity could be obtained by decreased bacterial conversion from primary bile acids. 3) Alternatively, bile acids could be sequestered by chemical binding agents, e.g. aluminium hydroxide (Al(OH)3) or probiotic bacteria. 4) Exogenous ursodeoxycholic acid (UDCA) can reduce the luminal proportion of secondary bile acids and also has direct anti-neoplastic activity on colonocytes in vitro.
E. Im and J. D. Martinez, Ursodeoxycholic acid (UDCA) can inhibit deoxycholic acid (DCA)-induced apoptosis via modulation of EGFR/ERK signalling in human colon cancer cells, J. Nutr., 2004, 134, 483. [Pg.98]

Igimi et al ) have predicted that the precipitation of GUDC could occur during treatment with GUDC. Bateson et al°I have reported that 122 patients with cholesterol gall stones vrfiich can not take the picture even by Roentgen were treated with chenodeoxycholic acid(CDCA) cind 56 patients were treated with ursodeoxycholic acid(UDCA) for six months or more. Six of the 56 patients treated with UDCA developed calcification, but none of the patients treated with CDCA showed any evidence of calcification on the surface of the... [Pg.256]

Fig. 5.4.6 Mass chromatograms of pentafluorobenzyl bromide-trimethylsilylimidazole derivatives of BA standards (reprinted from [18]). 1 3j5-hydroxychol-5-enic acid, 2 LCA, 3 DCA, 4 CDCA, 5 hyodeoxycholic acid (HDCA), 6 ursodeoxycholic acid (UDCA), 7 [ll,12-d2] CDCA,... Fig. 5.4.6 Mass chromatograms of pentafluorobenzyl bromide-trimethylsilylimidazole derivatives of BA standards (reprinted from [18]). 1 3j5-hydroxychol-5-enic acid, 2 LCA, 3 DCA, 4 CDCA, 5 hyodeoxycholic acid (HDCA), 6 ursodeoxycholic acid (UDCA), 7 [ll,12-d2] CDCA,...
Scalia and Games developed a packed column SFC method for the analysis of free bile acids cholic acid (CA), chenodeoxycholic acid (CDCA), deoxycholic acid (DCA), lithocholic acid (LCA), and ursodeoxycholic acid (UDCA) [32]. The baseline separation of all five bile acids was achieved on a packed phenyl column with a methanol-modified carbon dioxide in less than 4 min. The elution order showed a normal-phase mechanism because the solutes eluted in the order of increasing polarity following the number of hydroxyl groups on the steroid nucleus. The method was also applied to the assay of UDCA and CDCA in capsule and tablet formulations. The method was found to be linear in the range 1.5-7.5 ng/ml (r > 0.99, n = 6). The average recoveries (n= 10) for UDCA and CDCA were 100.2% with a RSD of 1.7% and 101.5% with a RSD of 2.2%, respectively. The reproducibility of the method was less than 1.5% (n = 10) for both UDCA and CDCA. [Pg.137]

Floreani, A., Zappala, F., Mazzetto, M., Naccarato, R., Plebani, M., Chiaramonte, M. Different response to ursodeoxycholic acid (UDCA) in primary biliary cirrhosis according to severity of disease. Dig. Dis. Sci. 1994 39 9-14... [Pg.668]

If cholestasis is not present, the additional application of ursodeoxycholic acid (UDCA) is worth considering because of its pharmacological properties and lack of side effects or interactions. Initial results on the treatment of chronic hepatitis with UDCA were reported by F. IcHiDA (1961), T. Nakahara et al. (1975) and K. Miyaji (1976). (s. p. 705) In 1988 our study group also noted obvious and permanent effects of UDCA on the course of disease in terms of clinical and laboratory indices in severe acute viral hepatitis B. (s. p. 437) Such observations were confirmed by A. Jorge in 1993. Owing to the multiple mechanisms of action of UDCA, in particular its immunomodulatory effect, adjuvant therapeutic efficacy can be anticipated in autoimmune hepatitis, as reported by P. Janowitz et al. in 1996. In autoimmune-associated chronic hepatitis C, UDCA proved to be a successful therapeutic agent (K. Nakamura et al., 1999). [Pg.686]

Nature of compounds. No correlation was found between Dr and Ds of six salts of ursodeoxycholic acid (UDCA). Although Ds showed that the salts had smooth surfaces, their Dr values were high. UDCA acted as a surfactant to increase the dissolution rate. Similarly, surfactant properties of diclofenate anions were found responsible for Dr being higher than Ds. " ... [Pg.1797]

Ursodiol (ursodeoxycholic acid—UDCA), a bile acid with gallstone-stabilizing properties (8 to 10 mg/kg/day), is used for dissolution of radiolucent gallbladder stones and to increase the flow of bile in patients with bile duct prosthesis or stents. [Pg.717]

Ursodeoxycholic acid (UDCA ursodiol, actigall) (Figure 37-4) is a hydrophilic, dehydroxylated bile acid that is formed by epimerization of chenodeoxycholic acid (CDCA chenodiol) in the gut by intestinal bacteria it comprises l-3% of the total bile acid pool. When administered orally, litholytic bile acids such as chenodiol and ursodiol can alter relative concentrations of bile acids, decrease biliary lipid secretion, and reduce the cholesterol content of the bile so that it is less lith-ogenic. Ursodiol also may have cytoprotective effects on hepatocytes and effects on the immune system that account for some of its beneficial effects in cholestatic liver diseases. [Pg.652]

Ursodeoxycholic acid (UDCA), cholic acid (CA), chenodeoxycholic acid (CDCA), deoxycholic acid (DCA), lithocholic acid (LCA), and their glyco and tauro-derivatives (Figure 19.7) play an important role in biological systems. Their biological functions are principally associated with lipid digestion and absorption. [Pg.513]

Cholesterol absorption during bile acid feeding Effect of ursodeoxycholic acid (UDCA) administration. Gastroenterology, 78 214-219 (1980). [Pg.60]


See other pages where Ursodeoxycholic acid UDCA is mentioned: [Pg.12]    [Pg.277]    [Pg.3]    [Pg.101]    [Pg.133]    [Pg.632]    [Pg.608]    [Pg.185]    [Pg.857]    [Pg.205]    [Pg.277]    [Pg.75]    [Pg.226]    [Pg.151]    [Pg.444]    [Pg.272]   
See also in sourсe #XX -- [ Pg.180 ]




SEARCH



Ursodeoxycholate

Ursodeoxycholic acid

© 2024 chempedia.info